Has Jason Bermak received payments from drug or device companies?

Yes. Drug and device makers reported $953,212 in general payments to Jason Bermak across 896 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Jason Bermak did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Jason Bermak come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Jason Bermak

Psychiatry · San Rafael, CANPI 1093844128

Payments from drug & device makers

What this record shows

This record is dominated by speaking fees: $781,704 of the $953,212 with a category attached, or 82.0%. 12 manufacturers reported payments, led by Otsuka America Pharmaceutical, Inc. at 35.9% of the total. Reporting peaked in 2019 at $308,277 and has fallen 72.7% since, to $84,258 in 2025. Among psychiatry clinicians in CA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$953,212in general payments, 2019–2025

Across 896 payments — averaging $1063.85 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

Otsuka America Pharmaceutical, Inc.$342K
ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$325K
Johnson & Johnson$87K
Sunovion Pharmaceuticals Inc.$74K
Teva Pharmaceuticals USA, Inc.$39K
Alkermes, Inc.$30K
plus $56K from 6 others

$565,939in research payments, 2019–2025

Across 165 payments — averaging $3429.93 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

Otsuka Pharmaceutical Development & Commercialization, Inc.$204K
Janssen Research & Development, LLC$182K
Biogen$118K
Livanova USA, Inc.$55K
Teva Pharmaceuticals USA, Inc.$7K

What the payments were for

Consulting fees$59,6466%
Speaking & faculty fees$781,70482%
Travel & lodging$92,97010%
Food & beverage$18,8522%
Education$400%

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
Otsuka America Pharmaceutical, Inc.	351	$342,139
ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)	264	$325,150
Johnson & Johnson	87	$87,098
Sunovion Pharmaceuticals Inc.	73	$73,566
Teva Pharmaceuticals USA, Inc.	29	$39,138
Alkermes, Inc.	22	$30,223
Neurocrine Biosciences, Inc.	29	$23,326
Axsome Therapeutics, Inc.	25	$20,850
E.r. Squibb & Sons, L.L.C.	8	$8,883
H. Lundbeck A S	2	$2,449
Vanda Pharmaceuticals Inc.	2	$310
AbbVie(2 entities)	4	$81

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

CAPLYTA$322,274
REXULTI$287,424
LATUDA$72,793
LYBALVI$68,334
ARISTADA$60,389
ABILIFY MAINTENA$53,391
INVEGA SUSTENNA$50,576
INVEGA TRINZA$49,896
AUSTEDO$39,099
SPRAVATO$36,000
INGREZZA$23,060
Auvelity$20,434
ARISTADA INITIO$3,300
VIVITROL$960
Fanapt$284

How this compares

$953,212 in reported general payments places this provider in the 95th percentile of 4,954 psychiatry providers in California.

See all psychiatry providers in California →

Most prescribed under Part D

Drug	Claims	Cost to plans & patients
NuedextaDextromethorphan Hbr/Quinidine	13	$19,142
AuvelityDextromethorphan Hbr/Bupropion	13	$18,578
Modafinil	13	$474
Gabapentin	16	$306
Lamotrigine	20	$230
Fluoxetine Hcl	13	$112

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

Company	Paid to this provider	Part D cost of their drugs
Axsome Therapeutics, Inc.Auvelity	$20,850	$18,57813 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 4,954 psychiatry providers in California.

Other psychiatry in San Rafael

Gustavo AlvaOrange$5.8M
John KooSan Francisco$3M
Jason KelloggIrvine$2.7M
Jonathan MeyerSan Diego$2.3M
Charles Tuan-Tu NguyenIrvine$2.1M
Manoj WaikarLos Gatos$1.9M
Gerald MaguireSan Juan Capistraco$1.8M
Salima BrillmanSunnyvale$1.4M
Bibi DasStanford$1.4M
Konstantinos TripodisBurbank$1M

See the full list for California →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →